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Abstract
After androgen ablation therapy (AAT), advanced prostate cancer (Pca) eventually progresses to castration-resistant
Pca (CRPC); however, the biomarkers that are used to predict its prognosis are limited. In this study, serum samples
from four patients with advanced Pca were collected at the time of the initial diagnosis and 3 months after AAT.
Proteomic changes were analyzed with two-dimensional differential in-gel electrophoresis and matrix-assisted laser
desorption/ionization time-of-flightmass spectrometry. Altogether, nine proteinswere differentially expressed in the sam-
ples collected at diagnosis and in the samples collected after AAT. Among them, the expression of transthyretin (TTR)
was 1.58-fold lower and clusterin (CLU) was 1.51-fold higher in the sera of post-AAT patients comparedwith those in the
sera from pre-AAT patients. The significant changes in serum TTR and CLU in post-AAT patients were further confirmed
by a large-scale ELISA. Immunohistochemistical staining revealed that the expression levels of TTR and CLU were sig-
nificantly higher in Pca tissue than in normal and benign prostate hyperplasia tissue. The expression levels of TTR and
CLU in Pca tissuewere found to be associatedwith the grade and stage of Pca. Overall, this study indicated that TTR and
CLU might be used to monitor the efficacy of AAT therapy and serve as biomarkers for the prognosis of Pca.
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Introduction
Prostate cancer (Pca) continues to be one of the most frequently diag-
nosed malignancies and a leading cause of cancer-related death among
men in the United States [1]. Patients with organ-confined Pca can
be cured with a radical prostatectomy or radiation therapy, whereas
for patients with advanced tumors, androgen ablation therapy (AAT)
still remains the most commonly used palliative treatment and the only
effective method for the treatment of the cancer [2,3]. Although the
tumor size decreases and the symptoms are alleviated soon after
AAT, unfortunately, the majority of Pca patients will eventually prog-
ress to androgen-resistant Pca (ARPC), which leads to mortality [4].
Several mechanisms have been proposed to be involved in the progres-
sion of Pca. It has been suggested that the signaling pathways mediated
by the androgen receptor [5–7] may play a role in this process. In
addition, genomic instability has been shown to cause and promote
the emergence of ARPC cells [8,9]. However, the exact mechanism
of androgen resistance is still unknown.
It is well known that Pca is an epithelial-derived form of malignancy
[10]. Some proteins, such as PSA, can leak out from the tissue into the
blood and serve as diagnostic and prognostic markers [11–16]. With
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the development of proteomic technologies, serum proteomic profiling
has emerged as a new screening method for Pca markers [17,18]. In
this study, we analyzed the proteomic changes in the sera of patients
with advanced Pca before AAT and 3 months after AAT using two-
dimensional differential in-gel electrophoresis (DIGE) and matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOFMS). Several interesting proteins identified in the proteo-
mic analysis were further studied by ELISA and immunohistochemistry
(IHC) in samples from Pca patients.
Materials and Methods
Serum Sample Preparation
At the early stage of this study, four Pca patients were enrolled (ages,
65-77 years; prostate-specific antigen [PSA] levels, 22.3-55.6 ng/ml).
The patients were diagnosed with advanced Pca by prostate biopsy,
magnetic resonance imaging, and a nuclear bone scan. Serum samples
were collected at the initial diagnosis of the disease and 3 months after
AAT (orchectomy).
Blood samples were collected in glass tubes without additives,
allowed to clot or sediment at room temperature for 1 hour, and cen-
trifuged at −4°C, 1500g for 15 minute. Aliquots of the serum were
collected and immediately stored at −80°C until further use. The iden-
tities of the patients from which the samples were taken were unknown
to the investigators participating in the study, and the samples con-
tained no features that would make it possible to identify the subjects.
The serum samples were processed using the ProteoPrep Blue Albumin
Depletion Kit (Sigma, St Louis, MO), which selectively removes albu-
min and immunoglobulin G from the serum sample, according to the
manufacturer’s instructions. The 2D Cleanup Kit (GE Healthcare,
Chalfont St Giles, United Kingdom) was used to purify the protein
extract samples before the determination of the sample concentrations
with the 2D Quant Kit (GE Healthcare).
CyDye Labeling
Previous studies have used a pooled internal standard during DIGE
to control for the variation between gels [19]. The protein extracts were
labeled using fluorescent cyanine dyes (GE Healthcare) developed
for two-dimensional DIGE technology following the manufacturer’s
protocols. The internal standard was prepared by combining equal
portions of each of the eight test samples. The samples from the pre-
and post-AAT groups were analyzed on four DIGE gels. The proteins
(50 μg) from the pre- or post-AAT samples were labeled with Cy3
or Cy5, respectively, and 50 μg of the internal standard mixture was
labeled with Cy2. The samples were incubated on ice for 30 minutes
in the dark. The reactions were then quenched with the addition of
1 μl of 10 mM lysine for 10 minutes on ice in the dark. The quenched
Cy3- and Cy5-labeled samples and the Cy2-labeled internal standard
were pooled before analysis with two-dimensional DIGE. Meanwhile,
two preparative gels, each containing 500 μg of the unlabeled mixture
of internal standard proteins, were analyzed.
Two-dimensional DIGE
Two-dimensional DIGE was performed as previously described
[19]. Briefly, immobilized dry strip (pH 4-7, NL 24 cm; GE Health-
care) was rehydrated for 12 hours in 450 μl of the rehydration buffer
(7 M urea, 2 M thiourea, 4% wt/vol CHAPS, and 1% vol/vol IPG
buffer, pH 4-7) using an Ettan IPGphor apparatus (GE Healthcare).
After isoelectric focusing (IEF), the proteins were reduced and alkylated
by successive 15-minute treatments with equilibration buffer contain-
ing 2% wt/vol DTT followed by 2.5% wt/vol iodoacetamide. The pro-
teins were resolved in the second dimension on a 12.5% SDS-PAGE gel
(24 cm× 20 cm) using an Ettan DALTsix instrument (GE Healthcare).
The resolved proteins were then scanned with the Typhoon 9400 im-
ager (Amersham, Biosciences, Uppsala, Sweden). The two preparative
gels were stained with the Deep Purple Total Protein Stain (RPN6306;
GE Healthcare) and scanned with a Typhoon 9400 imager.
DIGE Analysis
After the images were scanned, the GEHealthcare DeCyder software
v6.0 was used for the differential gel analysis. The two-dimensional
image of the gel from each post-AAT sample was compared to that
of the pre-AAT sample after normalization to the internal standard
sample. Relative protein quantitation across all the pre-AAT and post-
AAT samples was performed with the software. The protein spots with
significant differences in abundance (>1.5-fold) [19] were selected from
the stained gels for further analysis.
Automated Protein Spot Handling
The protein spots chosen for the MALDI-TOF MS analysis were
analyzed with an Ettan Spot HandlingWorkstation (GEHealthcare) as
previously described [19]. In the automated procedure, the selected
protein spots in the deep purple–stained gels were cut out, washed with
50 mM NH4HCO3 and 50% vol/vol methanol, and digested with
20 ng/μl trypsin (sequencing-grade; Promega, Madison, WI) in 20 mM
NH4HCO3 for 2 hours at 37°C. The tryptic peptides were extracted
with 50% vol/vol acetonitrile (ACN) and 0.5% vol/vol trifluoroacetic
acid (TFA). The peptide samples were then dissolved in 5 mg/ml
CHCA matrix in 50% vol/vol ACN and 0.1% vol/vol TFA. Finally,
the samples were spotted on the MS sample plate.
MALDI-TOF MS and Database Searching
MALDI peptide mass fingerprinting (PMF) was performed on
an Ettan MALDI-TOF mass spectrometer (GE Healthcare) operating
in reflection mode. An internal calibration was performed using the
trypsin autodigestion peaks at m/z 842.509 and 2211.104. Each spec-
trum corresponded to the sum of 200 acquisitions, each of eight laser
pulses, for which the signal-to-noise ratio exceeded a set threshold value.
Protein identification by PMF was performed using the MASCOT
search engine (http://www.matrixscience.com/cgi/search_form.pl?
FORMVER=2&SEARCH=PMF). The following parameters were
used in the searches: trypsin digest, onemissed cleavage allowed; species,
Homo sapiens; mass value, monoisotropic; peptide tolerance, 50 ppm;
and databases, NCBI and SWISS-PROT. The proteins that had signifi-
cantly high MASCOT scores (P < .05) for the PMF and corresponded
to at least four peptide hits were considered to be credibly identified.
ELISA
The serum levels of transthyretin (TTR) and clusterin (CLU) were
determined by an ELISA. Serum samples were obtained from 20 pre-
AAT patients, 20 post-AAT patients, and 20 ARPC patients. Com-
mercially available ELISA kits were used to assess the levels of CLU
(Biovendor, Modrice, Czech Republic) and TTR (Immundiagnostik,
Bensheim, Germany) in the serum. The serum TTR and CLU levels
were determined by a sandwich enzyme immunoassay. The median
serum CLU and TTR levels in five healthy patients were 70.90 ng/ml
(range from 63.72 to 96.30 ng/ml) and 14.51 ng/ml (range from 9.11
to 16.09 ng/ml), respectively.
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Immunohistochemistry
IHC studies were performed using the avidin-biotin complex method
as described previously [20]. In brief, sections were deparaffinized and
rehydrated. Endogenous peroxidase activity was blocked with 3%
hydrogen peroxide for 20 minutes. For antigen retrieval, the slides were
heated in a microwave oven for 10 minutes in 10 mM citrate buffer,
pH 6.0. Nonspecific binding was blocked with 10% normal rabbit
serum for 10 minutes at room temperature. Incubation with the TTR
and CLU monoclonal primary antibodies (Abcam, Cambridge, United
Kingdom) was performed at 37°C for 60 minutes at a dilution of 1:100.
Nonimmunemouse sera were included as negative controls. After a brief
wash, the slides were incubated with avidin-biotin immunoperoxidase
and developed with diaminobenzidine tetrahydrochloride at room tem-
perature. The cytoplasmic and nuclear expression levels of TTR and
CLU were evaluated. Immunostaining of TTR and CLU in the cyto-
plasm was evaluated with a semiquantitative scoring system. Briefly,
both the staining intensity and the percentage of positively stained tumor
cells were recorded. A staining index was obtained by times the inten-
sity of cytoplasmic staining (weak = 1, moderate = 2, strong = 3) with
the proportion of immunopositive tumor cells (<10% = 1, 10% and
50% = 2, >50% = 3). Thus, the values of the staining index ranged
from 1 to 9. Immunostaining of TTR and CLU in the nucleus was
scored according to the percentage of cells with stained nuclei. Lost
samples, unrepresentative samples, and samples with too few tumor
cells (<100 cells) were excluded from the data analysis. All the IHC re-
sults were evaluated by 2 independent pathologists who were unaware
of the clinical data. When the observers disagreed about results on the
same slide, the data were reviewed again until a consensus was reached.
The normal prostate tissues were obtained from patients who had
received radical cystectomies to treat bladder cancer. The benign
prostate hyperplasia (BPH) samples were obtained from patients
who had received transurethral resections of the prostate to treat BPH.
The prostate cancer (Pca) specimens were from prostate biopsies
or patients who had received radical prostatectomies for Pca. All
these specimens were collected from the Department of Pathology in
our hospital.
All the patients were clearly informed about the purpose of our
investigation and signed informed consent forms to be involved in
the study. The study was approved by the Sun Yat-sen University
review board and local committee.
Statistical Analysis
The SPSS software version 13.0 (SPSS, Inc, Chicago, IL) was used for
the statistical analysis. The data were analyzed using a variety of methods.
Student’s t test was used to analyze differences in the proteomics results.
A one-way analysis of variance was used to determine differences in the
ELISA results. Fisher exact test was used to determine the differences in
the IHC results. P < .05 was considered statistically significant.
Results
Fourteen Differentially Expressed Proteins Were Found
by Two-dimensional DIGE Analysis and Identified with
MALDI-TOF MS Analysis
To analyze the difference of serum proteomes between pre- and
post-AAT patients, the serum proteins were collected and separated
as described in the methods section. A representative two-dimensional
DIGE gel is shown in Figure 1. A comparative analysis using the
Figure 1. The spots marked with numbers indicate proteins whose
abundance was significantly different between pre- and post-AAT
samples, with 95% confidence levels.
Table 1. Comparison of CLU Expression in the Sera of Pre-AAT and Post-AAT Advanced Pca Patients.
ID Protein Name Accession No. % Coverage MS Score P Peptides Matched Mass (kDa) pI t Test Average Ratio
Upregulated
280 Macroglobulin α2 gi|224053 10 92 .00016 10 162.1 5.95 0.034 2.14
419 Macroglobulin α2 gi|224053 22 70 .028 5 162.07 5.95 0.009 1.93
424 Macroglobulin α2 gi|224053 7 88 .00038 8 162.07 5.95 0.0075 1.84
425 Macroglobulin α2 gi|224053 8 92 .00015 9 162.07 5.95 0.018 2.07
1091 HP protein gi|47124562 31 104 1e−05 10 31.6 8.48 0.025 2.12
1092 HP protein gi|47124562 32 117 5.2e−07 8 31.65 8.48 0.015 1.87
1126 CLU precursor gi|26665859 38 74 .011 5 16.27 5.60 0.0047 1.51
Downregulated
24 Fibronectin precursor gi|109658664 7 102 1.6e−05 12 243.1 5.6 0.039 −2.27
27 Fibronectin 1, isoform gi|119590936 8 75 .0086 8 111.89 5.35 0.027 −2.45
766 Human Fcari bound To Iga1-Fc gi|31615935 44 119 3.3e−07 8 23.64 7.12 0.004 −1.61
887 α2-HS glycoprotein gi|2521981 18 68 .039 5 36.27 5.20 0.026 −1.65
1165 Transthyretin precursor gi|55669575 63 183 1.3e−13 8 12.8 5.33 0.014 −1.58
1174 Apolipoprotein E precursor gi|4557325 27 99 3.2e−05 8 36.2 5.65 0.05 −3.26
1225 Igκ chain C region IGKC_HUMAN 50 79 .0035 4 11.8 5.58 0.0003 −1.77
1249 Anti-Entamoeba histolytica
immunoglobulin κ light chain
gi|5360675 32 78 .0044 4 23.4 7.81 0.012 −1.52
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DeCyder software showed that seven protein spots were increased
more than 1.5-fold in abundance and eight protein spots were de-
creased more than 1.5-fold in abundance in post-AAT sera compared
with pre-AAT sera (P < .05; Table 1).
Based on the two-dimensional DIGE analysis, the 15 differentially
expressed protein spots were selected for MS analysis. All the selected
protein spots were picked from the preparative gel and robotically
handled for the MALDI-TOF MS analysis. The PMF analysis and
database searching were described in the Materials and Methods
section. In total, 15 protein spots matched the PMF identification
criteria and were unambiguously identified. The PMF analysis results
are summarized in Table 1. After we excluded several spots identified
as the same proteins, our proteomics analysis found nine proteins that
changed expression levels in sera of Pca patients after AAT.
TTR Was Downregulated and CLU Was Upregulated in
the Sera of Pca Patients after AAT
In total, we identified three proteins that increased and six proteins
that decreased in abundance in the sera of Pca patients receiving AAT.
Among these proteins, TTR and CLU were chosen for further analysis
because they were previously reported to be associated with cancers
such as lung and ovarian cancers [21,22]. Although transferrin was also
reported to be associated with the development of some cancers, many
factors can influence its expression in the serum. Therefore, it was not
chosen for further analysis in this study.
TTR was found to be downregulated 1.58-fold in the sera of post-
AAT patients when compared with the sera of pre-AAT patients (Fig-
ure 2). Meanwhile, we found that the CLU precursor, corresponding
to a pI of 5.89 and a molecular mass (Mr) of 53 kDa, was upregulated
Figure 2. The expression level of TTR was downregulated in Pca patients receiving AAT compared with that in Pca patients before AAT.
(A) A map of the differences in the spots and a three-dimensional view of pre- and post-AAT samples. (B, C) A MALDI-TOF-MS reflection
spectrum of tryptic peptides from TTR; (D) matched peptides are shown in red. The underlined sequences were matched to the peptides
observed by MS. (E) Using these data, the MASCOT program searched the proteins in the Swiss-Prot database.
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1.51-fold in the four posttreatment serum samples compared with the
pretreatment serum samples (Figure 3).
To validate the differential expression of TTR and CLU, the sera
from the pre-AAT Pca, post-AATPca, and ARPC patients were analyzed
by an ELISA (Table 2). The results showed that the levels of CLU were
significantly higher in the posttreatment patients than in the pretreat-
ment patients. Interestingly, the levels of CLU in the patients receiving
AAT were even higher than the CLU levels in the ARPC patients (P <
.05). The levels of CLU in the ARPC patients were higher than those
in the pretreatment patients, but this difference was not statistically sig-
nificant. The TTR levels in the sera of the post-AAT and ARPC patients
were lower than the TTR levels in the pre-ATT patients (P < .05); how-
ever, the difference in the levels of TTR between the posttreatment and
ARPC patients did not reach statistical significance.
The Expressions Levels of TTR and CLU in Prostate Cancer
Tissue Were High and Correlated with the Gleason Score
and Stage of Pca
IHC was performed to assess whether the expression levels of
TTR and CLU were different for normal prostate, BPH, and Pca
tissues. Altogether, 10 normal prostate, 10 BPH, and 50 Pca tissue
slides were used for the IHC analysis. The results revealed that the
expression levels of TTR and CLU in Pca tissue were significantly
higher than those in normal prostate and BPH tissues (Tables 3 and
4 and Figures W1–W4). The high expression level of TTR in the Pca
tissues was in contrast to the lower expression level of TTR in the sera
of Pca patients (Table 3).
In addition, the expression levels of TTR and CLU in the Pca tis-
sues were found to correlate with the grade and stage of Pca. When
the grade and stage were high, the expression levels of TTR and CLU
were also high (Tables 3 and 4). These results indicated that TTR and
CLU may serve as biomarkers for the prognosis of Pca.
Discussion
It is important to predict the prognosis and the efficacy of AAT for late-
stage Pca. In this study, 14 proteins were identified in the serum of
post-AAT patients, of which 3 were significantly increased and 6 were
decreased compared with those in pre-AAT Pca samples. A MALDI-
TOF MS analysis revealed some of the unique proteins that may be
Figure 2. (continued).
128 TTR and CLU Correlate with AAT and Pca Malignancy Wang et al. Translational Oncology Vol. 5, No. 2, 2012
related to AAT. Among these differentially expressed proteins, TTR was
found to be downregulated in Pca patients receiving AAT. To confirm
that the downregulation of serum TTR in post-AAT patients was not
a rare occurrence, an ELISA was performed to determine the differential
expression levels of TTR in pretreatment, posttreatment and ARPC pa-
tients on a larger scale. The ELISA results showed that the serum levels
of TTR were significantly lower in the post-AAT and ARPC patients
than in the pre-AAT Pca patients, which confirmed the results from
the proteomic analysis. TTR is a tryptophan-rich protein [23]. Bauer
et al. [24] found that tryptophan metabolites, which may play a role
in pregnancy and can be used to introduce immunotolerance, may
suppress the activation of T cells. In our study, we found that TTR
was downregulated in the sera of Pca patient after AAT. Therefore,
the downregulation of TTRmay activate the immune system, thus lead-
ing to the death of Pca cells. Although the serum levels of TTR in the
ARPC patients were slightly lower than those in the post-AAT patients,
the difference was not statistically significant. However, the expression
level of TTR in the Pca tissue was significantly higher than in the normal
and BPH tissues, which was in contrast to the lower expression level of
TTR in the serum. Based on the theory of immunotolerance, which
can be induced by TTR, the high expression level of TTR in the tissue
can cause Pca cells to escape from immunological surveillance. Con-
versely, the lower expression level of TTR in the serum may stimulate
immunological activity and the subsequent death of cancer cells in Pca
patients; however, the high expression level of TTR in Pca tissue may
help Pca cells escape from immunological surveillance. However, there
are currently no other studies on TTR expression in cancer tissue to
confirm this hypothesis.
Figure 3. The expression level of CLU was upregulated in Pca patients receiving AAT compared with that of Pca patients before AAT.
(A) The differences in the spot map and the three-dimensional view between pre- and post-AAT samples. (B, C) The MALDI-TOF-MS
reflection spectrum of the tryptic peptides from CLU; (D) matched peptides are shown in red. The underlined sequences were matched
to the peptides observed by MS. (E) Using these data, the MASCOT program searched the proteins in the Swiss-Prot database.
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Previously, Kozak et al. [25] improved the detection rate of early
stage ovarian cancer by combining TTR with CA125. Moore et al.
[21] and Zhang et al. [22] described the identity of the discriminatory
peak of TTR (prealbumin) in ovarian cancer and regarded it as an early
diagnostic marker in ovarian cancer. Liu et al. [26] reported reduced
TTR expression levels in the sera of lung cancer patients. Therefore,
TTR could be combined with PSA testing to predict the progression of
Pca after AAT to compensate for the lack of specificity in PSA testing.
TTR is a transport protein for retinol-binding protein and thyroxin
and is rapidly turned over [27]. A previous study reported that the
intensity of the disease has no significant influence on serum TTR
levels, indicating that a change in the serum TTR level is a general
phenomenon that may associated with cancer-induced cachexia, which
is already present at early stages [28]. The downregulation of serum
TTR levels may be related to the nutritional status of the patient.
Therefore, the detailed function of TTR in the progression of Pca
warrants further study.
CLU is a secretory, sulfated glycoprotein that has antiapoptotic
properties [29–32] and has been recognized as an important prognostic
factor in Pca [33,34]. A higher CLU expression level was observed
after tumorigenesis induction and promotion in experimental prostate
carcinomas when compared with normal tissue in vivo. Sintich et al.
[35] reported that the mechanism by which CLU protects target cells
from cytotoxicity is at least partially mediated by an extracellular
mechanism. CLU was originally thought to be repressed by androgens.
Table 2. Serum Levels of CLU and TTR Determined by an ELISA Assay.
No. Mean ± SD (ng/ml) P
CLU
Pre-AAT 20 80.79 ± 19.82
Post-AAT 20 105.51 ± 28.43 .002*
ARPC 20 93.72 ± 25.55 .092†
TTR
Pre-AAT 20 19.82 ± 1.44
Post-AAT 20 17.88 ± 1.35 <.001*
ARPC 20 16.55 ± 2.06 <.001†
P represents the P value when the *post-AAT or †ARPC group was compared with the pre-AAT
group. P < .05 was considered significant.
Figure 3. (continued).
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However, it was later discovered that the increased CLU levels are most
likely due to castration-induced apoptosis of the prostatic epithelium
rather than the direct action of androgen. In addition, Cochrane et al.
[36] found that the CLU levels increased when tumors progressed to
androgen independence.
In this study, the serum level of CLU was 1.51-fold higher in Pca
patients after AAT than that in pre-AAT Pca patients, which is con-
sistent with previous reports [29,36,37]. It was thought that AAT
activated the high expression level of CLU. However, the level of
CLU at immediately following AAT may not be high enough to pre-
vent the AAT-induced apoptosis of Pca cells. As the amount of CLU
increases, its antiapoptotic effects will dominate the apoptotic effects
of AAT. This phenomenon may explain how Pca can be effectively
managed by AAT treatment during the early phase and how most
Pca patients who receive AAT will eventually progress to ARPC.
The IHC study revealed that the expression levels of TTR and CLU
were both higher in Pca tissue than in normal prostate and BPH tissue.
It also showed that the TTR and CLU expression levels in Pca tissue
were associated with the grade and stage of Pca. Higher expression levels
of TTR and CLU were found in tissues that scored higher on the
Gleason scale and were at later stages of Pca. As we mentioned above,
the higher expression levels of CLU in Pca tissues could provide Pca cells
with protection from apoptosis, and higher TTR levels in Pca tissues
may help Pca cells escape from immunological surveillance. Therefore,
the expression levels of TTR and CLU in Pca cancer tissue may serve
as predictive markers for Pca prognosis. To our knowledge, this is the
first report on TTR expression in Pca tissue and its relationship with the
grade and stage of Pca.
The insufficiency of our study is clear. Because no Pca patients
who received AAT were willing to allow biopsies when they were
still in the androgen-sensitive phase, we could not study the tissue
expression levels of TTR and CLU in these post-AAT Pca pa-
tients. Therefore, it was impossible to measure the trends in the TTR
and CLU levels as the patient progressed from androgen-sensitive to
androgen-resistant Pca.
In conclusion, we found a relationship between AAT and the se-
rum levels of TTR and CLU, and we found that their expression
levels in tissue correlate with Pca malignancy. Future studies will
focus on better understanding the biologic roles of these proteins
and their expression levels in ARPC after AAT. We also identified
a total of nine proteins in this study that were differentially expressed
before and after AAT. Therefore, the validation of the differential
Table 3. Expression Level of Transthyretin in Different Tissues and Its Relationship with Pca Malignancy.
Cases (No.) − Cases (No.) + Cases (No.) ++ Cases (No.) +++ Cases (No.) χ2, P
Specimen
NP 10 9 1 0 0
BPH 10 7 3 0 0
Pca 52 1 9 27 15
χ2 = 52.087, P < .001
Gleason
2-4 10 1 4 5 0
5-7 25 0 4 15 6
8-10 17 0 1 7 9
χ2 = 13.89, P = .046
Stage
A 6 1 3 2 0
B 24 0 5 17 2
C 14 0 1 7 6
D 8 0 0 1 7
χ2 = 27.15, P < .001
Gleason scores: 2-4 to 5-7, χ2 = 6.232, P = .145; 2-4 to 8-10, χ2 = 11.217, P = .014; 5-7 to 8-10: χ2 = 3.928, P = .269.
Stage: A to B, χ2 = 5.966, P = .166; A to C, χ2 = 8.026, P = .049; A to D, χ2 = 11.076, P = .007; B to C, χ2 = 6.078, P = .102; B to D, χ2 = 15.864, P = .001; C to D, χ2 = 4.032, P = .236.
Table 4. Expression Level of CLU in Different Tissues and Its Relationship with Pca Malignancy.
Cases (No.) − Cases (No.) + Cases (No.) ++ Cases (No.) +++ Cases (No.) χ2, P
NP 10 9 1 0 0
BPH 10 6 4 0 0
Pca 52 2 6 27 17
χ2 = 50.144, P < .001
Gleason
2-4 10 2 3 5 0
5-7 25 0 3 17 5
8-10 17 0 0 5 12
χ2 = 23.278, P = .001
Stage
A 6 2 2 2 0
B 24 0 4 16 4
C 14 0 0 8 6
D 8 0 0 1 7
χ2 = 25.282, P = .001
Gleason scores: 2-4 to 5-7, χ2 = 7.360, P = .082; 2-4 to 8-10, χ2 = 16.438, P = .001; 5-7 to 8-10, χ2 = 10.613, P = .010.
Stage: A to B, χ2 = 7.779, P = .067; A to C, χ2 = 10.247, P = .016; A to D, χ2 = 10.788, P = .009; B to C, χ2 = 4.306, P = .215; B to D: χ2 = 11.627, P = .006; C to D: χ2 = 4.053, P = .150.
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expression of other serum proteins identified in our study is also
warranted.
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Figure W1. Immunohistochemical localization of CLU in normal
human prostate tissue demonstrating weaker or no staining in the
nucleus and cytoplasm of luminal cells in normal glands.
Figure W2. Immunohistochemical localization of TTR in normal
human prostate tissue demonstrating weaker or no staining in the
nucleus and cytoplasm of luminal cells in normal glands.
Figure W3.Markedly stronger CLU-enhanced expression in malig-
nant epithelium seen in both nuclear staining and cytoplasm stain-
ing. Original magnification, ×40.
Figure W4. Markedly stronger TTR-enhanced expression in malig-
nant epithelium seen in both nuclear staining and cytoplasm stain-
ing. Original magnification, ×40.
